Published in British Journal of Clinical Pharmacology · View the paper (DOI)
A new study found that millions of unapproved antibiotics are being sold in India, with multinational companies manufacturing nearly 20% of the unapproved formulations. The researchers argue that banning the sale of unapproved FDC antibiotics and improving access to healthcare are crucial steps to controlling antimicrobial resistance.
Coverage from 2 institutions